Market Overview

Pfizer Confirms License of Families of Spinal Muscular Atrophy Quinazoline Drug Program from Repligen

Share:
Related RGEN
10 Stocks That Rallied Four Days, Then Sold Off Yesterday
15 Stocks Which Rallied Four Days, Then Sold Off Yesterday
Repligen's (RGEN) CEO Tony Hunt on Q4 2016 Results - Earnings Call Transcript (Seeking Alpha)
Related PFE
Carl Icahn's Track Record In Big Pharma
Icahn Takes Bristol-Myers Stake With M&A In Mind; Who Could Be The Acquirer?
A Dividend Portfolio Built From The World's Best Dividend ETFs (Seeking Alpha)

Repligen Corporation (NASDAQ: RGEN) announced today that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. (NYSE: PFE) to advance Repligen's spinal muscular atrophy (SMA) program, originally in-licensed from Families of SMA (FSMA).

Posted-In: News FDA

 

Related Articles (RGEN + PFE)

View Comments and Join the Discussion!